1 Anti-epileptic Drugs for Pediatrics Market Overview 1.1 Product Overview and Scope of Anti-epileptic Drugs for Pediatrics 1.2 Anti-epileptic Drugs for Pediatrics Segment by Type 1.2.1 Global Anti-epileptic Drugs for Pediatrics Market Value Comparison by Type (2023-2029) 1.2.2 1st Generation 1.2.3 2nd Generation 1.2.4 3rd Generation 1.3 Anti-epileptic Drugs for Pediatrics Segment by Application 1.3.1 Global Anti-epileptic Drugs for Pediatrics Market Value by Application: (2023-2029) 1.3.2 Hospitals 1.3.3 Retail Pharmacies 1.3.4 Online Pharmacies 1.4 Global Anti-epileptic Drugs for Pediatrics Market Size Estimates and Forecasts 1.4.1 Global Anti-epileptic Drugs for Pediatrics Revenue 2018-2029 1.4.2 Global Anti-epileptic Drugs for Pediatrics Sales 2018-2029 1.4.3 Global Anti-epileptic Drugs for Pediatrics Market Average Price (2018-2029) 1.5 Assumptions and Limitations 2 Anti-epileptic Drugs for Pediatrics Market Competition by Manufacturers 2.1 Global Anti-epileptic Drugs for Pediatrics Sales Market Share by Manufacturers (2018-2023) 2.2 Global Anti-epileptic Drugs for Pediatrics Revenue Market Share by Manufacturers (2018-2023) 2.3 Global Anti-epileptic Drugs for Pediatrics Average Price by Manufacturers (2018-2023) 2.4 Global Anti-epileptic Drugs for Pediatrics Industry Ranking 2021 VS 2022 VS 2023 2.5 Global Key Manufacturers of Anti-epileptic Drugs for Pediatrics, Manufacturing Sites & Headquarters 2.6 Global Key Manufacturers of Anti-epileptic Drugs for Pediatrics, Product Type & Application 2.7 Anti-epileptic Drugs for Pediatrics Market Competitive Situation and Trends 2.7.1 Anti-epileptic Drugs for Pediatrics Market Concentration Rate 2.7.2 The Global Top 5 and Top 10 Largest Anti-epileptic Drugs for Pediatrics Players Market Share by Revenue 2.7.3 Global Anti-epileptic Drugs for Pediatrics Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 2.8 Manufacturers Mergers & Acquisitions, Expansion Plans 3 Anti-epileptic Drugs for Pediatrics Retrospective Market Scenario by Region 3.1 Global Anti-epileptic Drugs for Pediatrics Market Size by Region: 2018 Versus 2022 Versus 2029 3.2 Global Anti-epileptic Drugs for Pediatrics Global Anti-epileptic Drugs for Pediatrics Sales by Region: 2018-2029 3.2.1 Global Anti-epileptic Drugs for Pediatrics Sales by Region: 2018-2023 3.2.2 Global Anti-epileptic Drugs for Pediatrics Sales by Region: 2024-2029 3.3 Global Anti-epileptic Drugs for Pediatrics Global Anti-epileptic Drugs for Pediatrics Revenue by Region: 2018-2029 3.3.1 Global Anti-epileptic Drugs for Pediatrics Revenue by Region: 2018-2023 3.3.2 Global Anti-epileptic Drugs for Pediatrics Revenue by Region: 2024-2029 3.4 North America Anti-epileptic Drugs for Pediatrics Market Facts & Figures by Country 3.4.1 North America Anti-epileptic Drugs for Pediatrics Market Size by Country: 2018 VS 2022 VS 2029 3.4.2 North America Anti-epileptic Drugs for Pediatrics Sales by Country (2018-2029) 3.4.3 North America Anti-epileptic Drugs for Pediatrics Revenue by Country (2018-2029) 3.4.4 U.S. 3.4.5 Canada 3.5 Europe Anti-epileptic Drugs for Pediatrics Market Facts & Figures by Country 3.5.1 Europe Anti-epileptic Drugs for Pediatrics Market Size by Country: 2018 VS 2022 VS 2029 3.5.2 Europe Anti-epileptic Drugs for Pediatrics Sales by Country (2018-2029) 3.5.3 Europe Anti-epileptic Drugs for Pediatrics Revenue by Country (2018-2029) 3.5.4 Germany 3.5.5 France 3.5.6 U.K. 3.5.7 Italy 3.5.8 Russia 3.6 Asia Pacific Anti-epileptic Drugs for Pediatrics Market Facts & Figures by Country 3.6.1 Asia Pacific Anti-epileptic Drugs for Pediatrics Market Size by Country: 2018 VS 2022 VS 2029 3.6.2 Asia Pacific Anti-epileptic Drugs for Pediatrics Sales by Country (2018-2029) 3.6.3 Asia Pacific Anti-epileptic Drugs for Pediatrics Revenue by Country (2018-2029) 3.6.4 China 3.6.5 Japan 3.6.6 South Korea 3.6.7 India 3.6.8 Australia 3.6.9 Taiwan 3.6.10 Indonesia 3.6.11 Thailand 3.6.12 Malaysia 3.6.13 Philippines 3.7 Latin America Anti-epileptic Drugs for Pediatrics Market Facts & Figures by Country 3.7.1 Latin America Anti-epileptic Drugs for Pediatrics Market Size by Country: 2018 VS 2022 VS 2029 3.7.2 Latin America Anti-epileptic Drugs for Pediatrics Sales by Country (2018-2029) 3.7.3 Latin America Anti-epileptic Drugs for Pediatrics Revenue by Country (2018-2029) 3.7.4 Mexico 3.7.5 Brazil 3.7.6 Argentina 3.8 Middle East and Africa Anti-epileptic Drugs for Pediatrics Market Facts & Figures by Country 3.8.1 Middle East and Africa Anti-epileptic Drugs for Pediatrics Market Size by Country: 2018 VS 2022 VS 2029 3.8.2 Middle East and Africa Anti-epileptic Drugs for Pediatrics Sales by Country (2018-2029) 3.8.3 Middle East and Africa Anti-epileptic Drugs for Pediatrics Revenue by Country (2018-2029) 3.8.4 Turkey 3.8.5 Saudi Arabia 3.8.6 U.A.E 4 Segment by Type 4.1 Global Anti-epileptic Drugs for Pediatrics Sales by Type (2018-2029) 4.1.1 Global Anti-epileptic Drugs for Pediatrics Sales by Type (2018-2023) 4.1.2 Global Anti-epileptic Drugs for Pediatrics Sales by Type (2024-2029) 4.1.3 Global Anti-epileptic Drugs for Pediatrics Sales Market Share by Type (2018-2029) 4.2 Global Anti-epileptic Drugs for Pediatrics Revenue by Type (2018-2029) 4.2.1 Global Anti-epileptic Drugs for Pediatrics Revenue by Type (2018-2023) 4.2.2 Global Anti-epileptic Drugs for Pediatrics Revenue by Type (2024-2029) 4.2.3 Global Anti-epileptic Drugs for Pediatrics Revenue Market Share by Type (2018-2029) 4.3 Global Anti-epileptic Drugs for Pediatrics Price by Type (2018-2029) 5 Segment by Application 5.1 Global Anti-epileptic Drugs for Pediatrics Sales by Application (2018-2029) 5.1.1 Global Anti-epileptic Drugs for Pediatrics Sales by Application (2018-2023) 5.1.2 Global Anti-epileptic Drugs for Pediatrics Sales by Application (2024-2029) 5.1.3 Global Anti-epileptic Drugs for Pediatrics Sales Market Share by Application (2018-2029) 5.2 Global Anti-epileptic Drugs for Pediatrics Revenue by Application (2018-2029) 5.2.1 Global Anti-epileptic Drugs for Pediatrics Revenue by Application (2018-2023) 5.2.2 Global Anti-epileptic Drugs for Pediatrics Revenue by Application (2024-2029) 5.2.3 Global Anti-epileptic Drugs for Pediatrics Revenue Market Share by Application (2018-2029) 5.3 Global Anti-epileptic Drugs for Pediatrics Price by Application (2018-2029) 6 Key Companies Profiled 6.1 Mylan N.V 6.1.1 Mylan N.V Corporation Information 6.1.2 Mylan N.V Description and Business Overview 6.1.3 Mylan N.V Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2018-2023) 6.1.4 Mylan N.V Anti-epileptic Drugs for Pediatrics Product Portfolio 6.1.5 Mylan N.V Recent Developments/Updates 6.2 Cephalon, Inc 6.2.1 Cephalon, Inc Corporation Information 6.2.2 Cephalon, Inc Description and Business Overview 6.2.3 Cephalon, Inc Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2018-2023) 6.2.4 Cephalon, Inc Anti-epileptic Drugs for Pediatrics Product Portfolio 6.2.5 Cephalon, Inc Recent Developments/Updates 6.3 GlaxoSmithKline plc 6.3.1 GlaxoSmithKline plc Corporation Information 6.3.2 GlaxoSmithKline plc Description and Business Overview 6.3.3 GlaxoSmithKline plc Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2018-2023) 6.3.4 GlaxoSmithKline plc Anti-epileptic Drugs for Pediatrics Product Portfolio 6.3.5 GlaxoSmithKline plc Recent Developments/Updates 6.4 Janssen Pharmaceuticals 6.4.1 Janssen Pharmaceuticals Corporation Information 6.4.2 Janssen Pharmaceuticals Description and Business Overview 6.4.3 Janssen Pharmaceuticals Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2018-2023) 6.4.4 Janssen Pharmaceuticals Anti-epileptic Drugs for Pediatrics Product Portfolio 6.4.5 Janssen Pharmaceuticals Recent Developments/Updates 6.5 Novartis AG 6.5.1 Novartis AG Corporation Information 6.5.2 Novartis AG Description and Business Overview 6.5.3 Novartis AG Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2018-2023) 6.5.4 Novartis AG Anti-epileptic Drugs for Pediatrics Product Portfolio 6.5.5 Novartis AG Recent Developments/Updates 6.6 Pfizer, Inc 6.6.1 Pfizer, Inc Corporation Information 6.6.2 Pfizer, Inc Description and Business Overview 6.6.3 Pfizer, Inc Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2018-2023) 6.6.4 Pfizer, Inc Anti-epileptic Drugs for Pediatrics Product Portfolio 6.6.5 Pfizer, Inc Recent Developments/Updates 6.7 Sanofi S.A 6.6.1 Sanofi S.A Corporation Information 6.6.2 Sanofi S.A Description and Business Overview 6.6.3 Sanofi S.A Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2018-2023) 6.4.4 Sanofi S.A Anti-epileptic Drugs for Pediatrics Product Portfolio 6.7.5 Sanofi S.A Recent Developments/Updates 6.8 UCB Pharma Limited 6.8.1 UCB Pharma Limited Corporation Information 6.8.2 UCB Pharma Limited Description and Business Overview 6.8.3 UCB Pharma Limited Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2018-2023) 6.8.4 UCB Pharma Limited Anti-epileptic Drugs for Pediatrics Product Portfolio 6.8.5 UCB Pharma Limited Recent Developments/Updates 6.9 Sunovion Pharmaceuticals Limited 6.9.1 Sunovion Pharmaceuticals Limited Corporation Information 6.9.2 Sunovion Pharmaceuticals Limited Description and Business Overview 6.9.3 Sunovion Pharmaceuticals Limited Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2018-2023) 6.9.4 Sunovion Pharmaceuticals Limited Anti-epileptic Drugs for Pediatrics Product Portfolio 6.9.5 Sunovion Pharmaceuticals Limited Recent Developments/Updates 6.10 Valeant Pharmaceuticals International, Inc 6.10.1 Valeant Pharmaceuticals International, Inc Corporation Information 6.10.2 Valeant Pharmaceuticals International, Inc Description and Business Overview 6.10.3 Valeant Pharmaceuticals International, Inc Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2018-2023) 6.10.4 Valeant Pharmaceuticals International, Inc Anti-epileptic Drugs for Pediatrics Product Portfolio 6.10.5 Valeant Pharmaceuticals International, Inc Recent Developments/Updates 6.11 Zogenix 6.11.1 Zogenix Corporation Information 6.11.2 Zogenix Anti-epileptic Drugs for Pediatrics Description and Business Overview 6.11.3 Zogenix Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2018-2023) 6.11.4 Zogenix Anti-epileptic Drugs for Pediatrics Product Portfolio 6.11.5 Zogenix Recent Developments/Updates 6.12 GW Pharmaceuticals 6.12.1 GW Pharmaceuticals Corporation Information 6.12.2 GW Pharmaceuticals Anti-epileptic Drugs for Pediatrics Description and Business Overview 6.12.3 GW Pharmaceuticals Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2018-2023) 6.12.4 GW Pharmaceuticals Anti-epileptic Drugs for Pediatrics Product Portfolio 6.12.5 GW Pharmaceuticals Recent Developments/Updates 6.13 Insys 6.13.1 Insys Corporation Information 6.13.2 Insys Anti-epileptic Drugs for Pediatrics Description and Business Overview 6.13.3 Insys Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2018-2023) 6.13.4 Insys Anti-epileptic Drugs for Pediatrics Product Portfolio 6.13.5 Insys Recent Developments/Updates 6.14 Zynerba 6.14.1 Zynerba Corporation Information 6.14.2 Zynerba Anti-epileptic Drugs for Pediatrics Description and Business Overview 6.14.3 Zynerba Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2018-2023) 6.14.4 Zynerba Anti-epileptic Drugs for Pediatrics Product Portfolio 6.14.5 Zynerba Recent Developments/Updates 7 Industry Chain and Sales Channels Analysis 7.1 Anti-epileptic Drugs for Pediatrics Industry Chain Analysis 7.2 Anti-epileptic Drugs for Pediatrics Key Raw Materials 7.2.1 Key Raw Materials 7.2.2 Raw Materials Key Suppliers 7.3 Anti-epileptic Drugs for Pediatrics Production Mode & Process 7.4 Anti-epileptic Drugs for Pediatrics Sales and Marketing 7.4.1 Anti-epileptic Drugs for Pediatrics Sales Channels 7.4.2 Anti-epileptic Drugs for Pediatrics Distributors 7.5 Anti-epileptic Drugs for Pediatrics Customers 8 Anti-epileptic Drugs for Pediatrics Market Dynamics 8.1 Anti-epileptic Drugs for Pediatrics Industry Trends 8.2 Anti-epileptic Drugs for Pediatrics Market Drivers 8.3 Anti-epileptic Drugs for Pediatrics Market Challenges 8.4 Anti-epileptic Drugs for Pediatrics Market Restraints 9 Research Finding and Conclusion 10 Methodology and Data Source 10.1 Methodology/Research Approach 10.1.1 Research Programs/Design 10.1.2 Market Size Estimation 10.1.3 Market Breakdown and Data Triangulation 10.2 Data Source 10.2.1 Secondary Sources 10.2.2 Primary Sources 10.3 Author List 10.4 Disclaimer

List of Tables Table 1. Global Anti-epileptic Drugs for Pediatrics Market Value Comparison by Type (2023-2029) & (US$ Million) Table 2. Global Anti-epileptic Drugs for Pediatrics Market Value Comparison by Application (2023-2029) & (US$ Million) Table 3. Global Anti-epileptic Drugs for Pediatrics Market Competitive Situation by Manufacturers in 2022 Table 4. Global Anti-epileptic Drugs for Pediatrics Sales (K Units) of Key Manufacturers (2018-2023) Table 5. Global Anti-epileptic Drugs for Pediatrics Sales Market Share by Manufacturers (2018-2023) Table 6. Global Anti-epileptic Drugs for Pediatrics Revenue (US$ Million) by Manufacturers (2018-2023) Table 7. Global Anti-epileptic Drugs for Pediatrics Revenue Share by Manufacturers (2018-2023) Table 8. Global Market Anti-epileptic Drugs for Pediatrics Average Price (USD/Unit) of Key Manufacturers (2018-2023) Table 9. Global Key Players of Anti-epileptic Drugs for Pediatrics, Industry Ranking, 2021 VS 2022 VS 2023 Table 10. Global Key Manufacturers of Anti-epileptic Drugs for Pediatrics, Manufacturing Sites & Headquarters Table 11. Global Key Manufacturers of Anti-epileptic Drugs for Pediatrics, Product Type & Application Table 12. Global Key Manufacturers of Anti-epileptic Drugs for Pediatrics, Date of Enter into This Industry Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 14. Global Anti-epileptic Drugs for Pediatrics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-epileptic Drugs for Pediatrics as of 2022) Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans Table 16. Global Anti-epileptic Drugs for Pediatrics Market Size by Region (US$ Million): 2018 VS 2022 VS 2029 Table 17. Global Anti-epileptic Drugs for Pediatrics Sales by Region (2018-2023) & (K Units) Table 18. Global Anti-epileptic Drugs for Pediatrics Sales Market Share by Region (2018-2023) Table 19. Global Anti-epileptic Drugs for Pediatrics Sales by Region (2024-2029) & (K Units) Table 20. Global Anti-epileptic Drugs for Pediatrics Sales Market Share by Region (2024-2029) Table 21. Global Anti-epileptic Drugs for Pediatrics Revenue by Region (2018-2023) & (US$ Million) Table 22. Global Anti-epileptic Drugs for Pediatrics Revenue Market Share by Region (2018-2023) Table 23. Global Anti-epileptic Drugs for Pediatrics Revenue by Region (2024-2029) & (US$ Million) Table 24. Global Anti-epileptic Drugs for Pediatrics Revenue Market Share by Region (2024-2029) Table 25. North America Anti-epileptic Drugs for Pediatrics Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million) Table 26. North America Anti-epileptic Drugs for Pediatrics Sales by Country (2018-2023) & (K Units) Table 27. North America Anti-epileptic Drugs for Pediatrics Sales by Country (2024-2029) & (K Units) Table 28. North America Anti-epileptic Drugs for Pediatrics Revenue by Country (2018-2023) & (US$ Million) Table 29. North America Anti-epileptic Drugs for Pediatrics Revenue by Country (2024-2029) & (US$ Million) Table 30. Europe Anti-epileptic Drugs for Pediatrics Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million) Table 31. Europe Anti-epileptic Drugs for Pediatrics Sales by Country (2018-2023) & (K Units) Table 32. Europe Anti-epileptic Drugs for Pediatrics Sales by Country (2024-2029) & (K Units) Table 33. Europe Anti-epileptic Drugs for Pediatrics Revenue by Country (2018-2023) & (US$ Million) Table 34. Europe Anti-epileptic Drugs for Pediatrics Revenue by Country (2024-2029) & (US$ Million) Table 35. Asia Pacific Anti-epileptic Drugs for Pediatrics Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million) Table 36. Asia Pacific Anti-epileptic Drugs for Pediatrics Sales by Region (2018-2023) & (K Units) Table 37. Asia Pacific Anti-epileptic Drugs for Pediatrics Sales by Region (2024-2029) & (K Units) Table 38. Asia Pacific Anti-epileptic Drugs for Pediatrics Revenue by Region (2018-2023) & (US$ Million) Table 39. Asia Pacific Anti-epileptic Drugs for Pediatrics Revenue by Region (2024-2029) & (US$ Million) Table 40. Latin America Anti-epileptic Drugs for Pediatrics Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million) Table 41. Latin America Anti-epileptic Drugs for Pediatrics Sales by Country (2018-2023) & (K Units) Table 42. Latin America Anti-epileptic Drugs for Pediatrics Sales by Country (2024-2029) & (K Units) Table 43. Latin America Anti-epileptic Drugs for Pediatrics Revenue by Country (2018-2023) & (US$ Million) Table 44. Latin America Anti-epileptic Drugs for Pediatrics Revenue by Country (2024-2029) & (US$ Million) Table 45. Middle East & Africa Anti-epileptic Drugs for Pediatrics Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million) Table 46. Middle East & Africa Anti-epileptic Drugs for Pediatrics Sales by Country (2018-2023) & (K Units) Table 47. Middle East & Africa Anti-epileptic Drugs for Pediatrics Sales by Country (2024-2029) & (K Units) Table 48. Middle East & Africa Anti-epileptic Drugs for Pediatrics Revenue by Country (2018-2023) & (US$ Million) Table 49. Middle East & Africa Anti-epileptic Drugs for Pediatrics Revenue by Country (2024-2029) & (US$ Million) Table 50. Global Anti-epileptic Drugs for Pediatrics Sales (K Units) by Type (2018-2023) Table 51. Global Anti-epileptic Drugs for Pediatrics Sales (K Units) by Type (2024-2029) Table 52. Global Anti-epileptic Drugs for Pediatrics Sales Market Share by Type (2018-2023) Table 53. Global Anti-epileptic Drugs for Pediatrics Sales Market Share by Type (2024-2029) Table 54. Global Anti-epileptic Drugs for Pediatrics Revenue (US$ Million) by Type (2018-2023) Table 55. Global Anti-epileptic Drugs for Pediatrics Revenue (US$ Million) by Type (2024-2029) Table 56. Global Anti-epileptic Drugs for Pediatrics Revenue Market Share by Type (2018-2023) Table 57. Global Anti-epileptic Drugs for Pediatrics Revenue Market Share by Type (2024-2029) Table 58. Global Anti-epileptic Drugs for Pediatrics Price (USD/Unit) by Type (2018-2023) Table 59. Global Anti-epileptic Drugs for Pediatrics Price (USD/Unit) by Type (2024-2029) Table 60. Global Anti-epileptic Drugs for Pediatrics Sales (K Units) by Application (2018-2023) Table 61. Global Anti-epileptic Drugs for Pediatrics Sales (K Units) by Application (2024-2029) Table 62. Global Anti-epileptic Drugs for Pediatrics Sales Market Share by Application (2018-2023) Table 63. Global Anti-epileptic Drugs for Pediatrics Sales Market Share by Application (2024-2029) Table 64. Global Anti-epileptic Drugs for Pediatrics Revenue (US$ Million) by Application (2018-2023) Table 65. Global Anti-epileptic Drugs for Pediatrics Revenue (US$ Million) by Application (2024-2029) Table 66. Global Anti-epileptic Drugs for Pediatrics Revenue Market Share by Application (2018-2023) Table 67. Global Anti-epileptic Drugs for Pediatrics Revenue Market Share by Application (2024-2029) Table 68. Global Anti-epileptic Drugs for Pediatrics Price (USD/Unit) by Application (2018-2023) Table 69. Global Anti-epileptic Drugs for Pediatrics Price (USD/Unit) by Application (2024-2029) Table 70. Mylan N.V Corporation Information Table 71. Mylan N.V Description and Business Overview Table 72. Mylan N.V Anti-epileptic Drugs for Pediatrics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023) Table 73. Mylan N.V Anti-epileptic Drugs for Pediatrics Product Table 74. Mylan N.V Recent Developments/Updates Table 75. Cephalon, Inc Corporation Information Table 76. Cephalon, Inc Description and Business Overview Table 77. Cephalon, Inc Anti-epileptic Drugs for Pediatrics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023) Table 78. Cephalon, Inc Anti-epileptic Drugs for Pediatrics Product Table 79. Cephalon, Inc Recent Developments/Updates Table 80. GlaxoSmithKline plc Corporation Information Table 81. GlaxoSmithKline plc Description and Business Overview Table 82. GlaxoSmithKline plc Anti-epileptic Drugs for Pediatrics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023) Table 83. GlaxoSmithKline plc Anti-epileptic Drugs for Pediatrics Product Table 84. GlaxoSmithKline plc Recent Developments/Updates Table 85. Janssen Pharmaceuticals Corporation Information Table 86. Janssen Pharmaceuticals Description and Business Overview Table 87. Janssen Pharmaceuticals Anti-epileptic Drugs for Pediatrics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023) Table 88. Janssen Pharmaceuticals Anti-epileptic Drugs for Pediatrics Product Table 89. Janssen Pharmaceuticals Recent Developments/Updates Table 90. Novartis AG Corporation Information Table 91. Novartis AG Description and Business Overview Table 92. Novartis AG Anti-epileptic Drugs for Pediatrics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023) Table 93. Novartis AG Anti-epileptic Drugs for Pediatrics Product Table 94. Novartis AG Recent Developments/Updates Table 95. Pfizer, Inc Corporation Information Table 96. Pfizer, Inc Description and Business Overview Table 97. Pfizer, Inc Anti-epileptic Drugs for Pediatrics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023) Table 98. Pfizer, Inc Anti-epileptic Drugs for Pediatrics Product Table 99. Pfizer, Inc Recent Developments/Updates Table 100. Sanofi S.A Corporation Information Table 101. Sanofi S.A Description and Business Overview Table 102. Sanofi S.A Anti-epileptic Drugs for Pediatrics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023) Table 103. Sanofi S.A Anti-epileptic Drugs for Pediatrics Product Table 104. Sanofi S.A Recent Developments/Updates Table 105. UCB Pharma Limited Corporation Information Table 106. UCB Pharma Limited Description and Business Overview Table 107. UCB Pharma Limited Anti-epileptic Drugs for Pediatrics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023) Table 108. UCB Pharma Limited Anti-epileptic Drugs for Pediatrics Product Table 109. UCB Pharma Limited Recent Developments/Updates Table 110. Sunovion Pharmaceuticals Limited Corporation Information Table 111. Sunovion Pharmaceuticals Limited Description and Business Overview Table 112. Sunovion Pharmaceuticals Limited Anti-epileptic Drugs for Pediatrics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023) Table 113. Sunovion Pharmaceuticals Limited Anti-epileptic Drugs for Pediatrics Product Table 114. Sunovion Pharmaceuticals Limited Recent Developments/Updates Table 115. Valeant Pharmaceuticals International, Inc Corporation Information Table 116. Valeant Pharmaceuticals International, Inc Description and Business Overview Table 117. Valeant Pharmaceuticals International, Inc Anti-epileptic Drugs for Pediatrics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023) Table 118. Valeant Pharmaceuticals International, Inc Anti-epileptic Drugs for Pediatrics Product Table 119. Valeant Pharmaceuticals International, Inc Recent Developments/Updates Table 120. Zogenix Corporation Information Table 121. Zogenix Description and Business Overview Table 122. Zogenix Anti-epileptic Drugs for Pediatrics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023) Table 123. Zogenix Anti-epileptic Drugs for Pediatrics Product Table 124. Zogenix Recent Developments/Updates Table 125. GW Pharmaceuticals Corporation Information Table 126. GW Pharmaceuticals Description and Business Overview Table 127. GW Pharmaceuticals Anti-epileptic Drugs for Pediatrics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023) Table 128. GW Pharmaceuticals Anti-epileptic Drugs for Pediatrics Product Table 129. GW Pharmaceuticals Recent Developments/Updates Table 130. Insys Corporation Information Table 131. Insys Description and Business Overview Table 132. Insys Anti-epileptic Drugs for Pediatrics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023) Table 133. Insys Anti-epileptic Drugs for Pediatrics Product Table 134. Insys Recent Developments/Updates Table 135. Zynerba Corporation Information Table 136. Zynerba Description and Business Overview Table 137. Zynerba Anti-epileptic Drugs for Pediatrics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023) Table 138. Zynerba Anti-epileptic Drugs for Pediatrics Product Table 139. Zynerba Recent Developments/Updates Table 140. Key Raw Materials Lists Table 141. Raw Materials Key Suppliers Lists Table 142. Anti-epileptic Drugs for Pediatrics Distributors List Table 143. Anti-epileptic Drugs for Pediatrics Customers List Table 144. Anti-epileptic Drugs for Pediatrics Market Trends Table 145. Anti-epileptic Drugs for Pediatrics Market Drivers Table 146. Anti-epileptic Drugs for Pediatrics Market Challenges Table 147. Anti-epileptic Drugs for Pediatrics Market Restraints Table 148. Research Programs/Design for This Report Table 149. Key Data Information from Secondary Sources Table 150. Key Data Information from Primary Sources List of Figures Figure 1. Product Picture of Anti-epileptic Drugs for Pediatrics Figure 2. Global Anti-epileptic Drugs for Pediatrics Market Value Comparison by Type (2023-2029) & (US$ Million) Figure 3. Global Anti-epileptic Drugs for Pediatrics Market Share by Type in 2022 & 2029 Figure 4. 1st Generation Product Picture Figure 5. 2nd Generation Product Picture Figure 6. 3rd Generation Product Picture Figure 7. Global Anti-epileptic Drugs for Pediatrics Market Value Comparison by Application (2023-2029) & (US$ Million) Figure 8. Global Anti-epileptic Drugs for Pediatrics Market Share by Application in 2022 & 2029 Figure 9. Hospitals Figure 10. Retail Pharmacies Figure 11. Online Pharmacies Figure 12. Global Anti-epileptic Drugs for Pediatrics Revenue, (US$ Million), 2018 VS 2022 VS 2029 Figure 13. Global Anti-epileptic Drugs for Pediatrics Market Size (2018-2029) & (US$ Million) Figure 14. Global Anti-epileptic Drugs for Pediatrics Sales (2018-2029) & (K Units) Figure 15. Global Anti-epileptic Drugs for Pediatrics Average Price (USD/Unit) & (2018-2029) Figure 16. Anti-epileptic Drugs for Pediatrics Report Years Considered Figure 17. Anti-epileptic Drugs for Pediatrics Sales Share by Manufacturers in 2022 Figure 18. Global Anti-epileptic Drugs for Pediatrics Revenue Share by Manufacturers in 2022 Figure 19. The Global 5 and 10 Largest Anti-epileptic Drugs for Pediatrics Players: Market Share by Revenue in 2022 Figure 20. Anti-epileptic Drugs for Pediatrics Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022 Figure 21. Global Anti-epileptic Drugs for Pediatrics Market Size by Region (US$ Million): 2018 VS 2022 VS 2029 Figure 22. North America Anti-epileptic Drugs for Pediatrics Sales Market Share by Country (2018-2029) Figure 23. North America Anti-epileptic Drugs for Pediatrics Revenue Market Share by Country (2018-2029) Figure 24. U.S. Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2018-2029) & (US$ Million) Figure 25. Canada Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2018-2029) & (US$ Million) Figure 26. Europe Anti-epileptic Drugs for Pediatrics Sales Market Share by Country (2018-2029) Figure 27. Europe Anti-epileptic Drugs for Pediatrics Revenue Market Share by Country (2018-2029) Figure 28. Germany Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2018-2029) & (US$ Million) Figure 29. France Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2018-2029) & (US$ Million) Figure 30. U.K. Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2018-2029) & (US$ Million) Figure 31. Italy Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2018-2029) & (US$ Million) Figure 32. Russia Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2018-2029) & (US$ Million) Figure 33. Asia Pacific Anti-epileptic Drugs for Pediatrics Sales Market Share by Region (2018-2029) Figure 34. Asia Pacific Anti-epileptic Drugs for Pediatrics Revenue Market Share by Region (2018-2029) Figure 35. China Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2018-2029) & (US$ Million) Figure 36. Japan Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2018-2029) & (US$ Million) Figure 37. South Korea Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2018-2029) & (US$ Million) Figure 38. India Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2018-2029) & (US$ Million) Figure 39. Australia Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2018-2029) & (US$ Million) Figure 40. Taiwan Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2018-2029) & (US$ Million) Figure 41. Indonesia Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2018-2029) & (US$ Million) Figure 42. Thailand Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2018-2029) & (US$ Million) Figure 43. Malaysia Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2018-2029) & (US$ Million) Figure 44. Philippines Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2018-2029) & (US$ Million) Figure 45. Latin America Anti-epileptic Drugs for Pediatrics Sales Market Share by Country (2018-2029) Figure 46. Latin America Anti-epileptic Drugs for Pediatrics Revenue Market Share by Country (2018-2029) Figure 47. Mexico Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2018-2029) & (US$ Million) Figure 48. Brazil Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2018-2029) & (US$ Million) Figure 49. Argentina Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2018-2029) & (US$ Million) Figure 50. Middle East & Africa Anti-epileptic Drugs for Pediatrics Sales Market Share by Country (2018-2029) Figure 51. Middle East & Africa Anti-epileptic Drugs for Pediatrics Revenue Market Share by Country (2018-2029) Figure 52. Turkey Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2018-2029) & (US$ Million) Figure 53. Saudi Arabia Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2018-2029) & (US$ Million) Figure 54. U.A.E Anti-epileptic Drugs for Pediatrics Revenue Growth Rate (2018-2029) & (US$ Million) Figure 55. Global Sales Market Share of Anti-epileptic Drugs for Pediatrics by Type (2018-2029) Figure 56. Global Revenue Market Share of Anti-epileptic Drugs for Pediatrics by Type (2018-2029) Figure 57. Global Anti-epileptic Drugs for Pediatrics Price (USD/Unit) by Type (2018-2029) Figure 58. Global Sales Market Share of Anti-epileptic Drugs for Pediatrics by Application (2018-2029) Figure 59. Global Revenue Market Share of Anti-epileptic Drugs for Pediatrics by Application (2018-2029) Figure 60. Global Anti-epileptic Drugs for Pediatrics Price (USD/Unit) by Application (2018-2029) Figure 61. Anti-epileptic Drugs for Pediatrics Value Chain Figure 62. Anti-epileptic Drugs for Pediatrics Production Process Figure 63. Channels of Distribution (Direct Vs Distribution) Figure 64. Distributors Profiles Figure 65. Bottom-up and Top-down Approaches for This Report Figure 66. Data Triangulation Figure 67. Key Executives Interviewed

Mylan N.V Cephalon, Inc GlaxoSmithKline plc Janssen Pharmaceuticals Novartis AG Pfizer, Inc Sanofi S.A UCB Pharma Limited Sunovion Pharmaceuticals Limited Valeant Pharmaceuticals International, Inc Zogenix GW Pharmaceuticals Insys Zynerba